The Harvard motor neurone disease drug developer secured the return of Amgen Ventures for its series A round.
Quralis, a US-based neurological disease medicine spinout of Harvard University, has raised $42m of series A funding from investors including Amgen Ventures, the corporate venturing arm of pharmaceutical firm Amgen Ventures.
UK government-backed investment unit Dementia Discovery Fund co-led the round together with LS Polaris Innovation Fund, Mission BioCapital, Inkef Capital and Droia Ventures.
The round also included Mitsui Global Investment, the corporate venturing arm of conglomerate Mitsui, and biotechnology firm Sanford Biosciences as well as Dolby Family…
